insights_auto
Kwa nini FARN imepungua kwa 3.92%?
Fahamu zaidichevron_right
FARN:LON
Faron Pharmaceuticals Oy
GBXÂ 35.07
arrow_downward
-3.92%(-1.43) Siku 1
13 Okt, 12:38:21 GMT +1 · GBX
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya FARN...
Fungua
GBXÂ 38.00
Juu
GBXÂ 38.00
Chini
GBXÂ 35.07
Mtaji wa soko
71.06M
Wastani wa kiasi cha mauzo
elfu 42.86
Kiasi cha mauzo ya hisa
elfu 26.30
Juu kwa wiki 52
GBXÂ 193.58
Chini kwa wiki 52
GBXÂ 34.00
EPS
-GBXÂ 0.10
Hisa za wawekezaji
31.03M
Idadi ya wafanyakazi
36
Fungua
GBXÂ 38.00
Juu
GBXÂ 38.00
Chini
GBXÂ 35.07
Mtaji wa soko
71.06M
Wastani wa kiasi cha mauzo
elfu 42.86
Kiasi cha mauzo ya hisa
elfu 26.30
Juu kwa wiki 52
GBXÂ 193.58
Chini kwa wiki 52
GBXÂ 34.00
EPS
-GBXÂ 0.10
Hisa za wawekezaji
31.03M
Idadi ya wafanyakazi
36
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
24/7 Wall St.
·
dakika 27 zilizopita
Buffett Says a Know-Nothing Investor Can Beat the Pros. $250 a Month in the S&P 500 Could Turn Into $508,000
The Motley Fool
·
dakika 33 zilizopita
If I Could Invest $1,000 in Just 1 Dividend Stock for the Next 5 Years, I'd Pick This Clear Standout Over the Vanguard S&P 500 ETF (VOO)
WSJ
·
saa 3 zilizopita
Nasdaq Futures Fall as Global AI Selloff Intensifies
CoinDesk
·
saa 7 zilizopita
Bitcoin rebounds above $83,000 as it decouples from tumbling Korean stocks and Nasdaq futures
Wasifu
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Kuhusu Faron Pharmaceuticals Oy
Afisa Mkuu Mtendaji (CEO)Markku Jalkanen
Wafanyakazi36
Lilianzishwa2003
Makao makuu-
Sekta-
Tovutifaron.com